Is HRT Safe? What the 2022 Evidence Actually Says — and What the 2002 WHI Study Got Wrong

Bottom line: The 2002 WHI study that generated widespread HRT fear was conducted primarily in women who were on average 63 years old, 12 years post-menopause, using synthetic progestins — not bioidentical progesterone. The 2022 Menopause Society and British Menopause Society both concluded that HRT benefits outweigh risks for most healthy women under 60 within 10 years of menopause onset. The safety evidence for bioidentical hormones specifically is more favorable than the synthetic formulations evaluated in the original WHI.

---

Why There Is So Much Confusion About HRT Safety

In 2002, the Women’s Health Initiative published results that sent a generation of women off hormone therapy. Headlines declared HRT dangerous. Millions of prescriptions were discontinued. Women in the middle of perimenopause were told by their doctors to manage symptoms without hormones.

What the coverage missed: the WHI study had significant design problems that distorted the safety picture.

The average participant was 63 years old — the mean time since last menstrual period was 12 years. Many participants had cardiovascular risk factors established over that decade-plus gap. The progestin used was synthetic medroxyprogesterone acetate, not bioidentical progesterone. The estrogen was oral conjugated equine estrogen, not transdermal estradiol.

Subsequent re-analyses of the same WHI data — controlling for age at initiation and health status at enrollment — produced a substantially different picture for younger women starting HRT in the timing window.

---

The Timing Hypothesis: Why When You Start Matters

The most important shift in HRT safety understanding since 2002 is the timing hypothesis: HRT has different effects when started within 10 years of menopause versus more than 10 years after.

The WHI participants who started HRT before age 60 or within 10 years of menopause showed:

• A trend toward reduced all-cause mortality
• Reduced coronary heart disease incidence
• A breast cancer risk signal that was smaller and slower to develop than in the late-initiator group

The 2022 British Menopause Society statement summarized the current evidence this way: “For most women under 60 who are within 10 years of menopause and have no contraindications, the benefits of HRT outweigh the risks.”

The North American Menopause Society reached the same conclusion in their 2022 Hormone Therapy Position Statement. Neither organization hedges on this for the timing-window population.

---

Bioidentical vs Synthetic: What the Evidence Shows

The WHI study used synthetic progestins. The safety data from that study — particularly regarding breast cancer and cardiovascular outcomes — may not apply directly to bioidentical progesterone.

The most rigorous evidence on this distinction is the French E3N cohort (Fournier et al., Breast Cancer Research, 2005 and follow-up studies): 80,000 French women followed for 8 years. Findings:

• Transdermal estradiol plus synthetic progestin: elevated breast cancer risk (RR approximately 1.4)
• Transdermal estradiol plus bioidentical progesterone: no elevated breast cancer risk (RR approximately 1.0)
• The difference between progestin types was statistically significant

This is observational data — not an RCT — but it is the best available evidence on the bioidentical progesterone question, and it points consistently toward a more favorable profile than synthetic alternatives.

The KEEPS trial (Kronos Early Estrogen Prevention Study) randomized women to transdermal estradiol, oral conjugated estrogen, or placebo within 3 years of menopause. After 4 years, neither HRT arm showed increased cardiovascular events, cognitive decline, or breast cancer — opposite to what the WHI found in the older, late-initiator population.

---

The Blood Clot and Stroke Question

Oral estrogen (including conjugated equine estrogen) is associated with increased blood clot (VTE) risk because oral estrogen undergoes first-pass liver metabolism, which affects clotting factors.

Transdermal estradiol — delivered through the skin, bypassing first-pass liver processing — does not show the same VTE elevation in the evidence base. The ESTHER study and subsequent analyses found no elevated VTE risk with transdermal estradiol versus placebo.

Winona uses transdermal estradiol (patch or cream) rather than oral conjugated estrogen. This formulation choice matters for the VTE risk question.

---

What Current Medical Guidelines Say

As of 2022–2023, the major menopause society positions are:

North American Menopause Society (NAMS): “HRT is the most effective treatment for vasomotor symptoms and is approved for the prevention of osteoporosis. For healthy symptomatic women who are younger than 60 or within 10 years of menopause onset, the benefits of systemic HRT outweigh the risks.”

British Menopause Society: “All women with menopause symptoms should have access to HRT… The risks of HRT are frequently overstated and the benefits underplayed.”

International Menopause Society: “Menopausal hormone therapy (MHT) is effective for vasomotor symptoms and reduces the risk of osteoporosis fracture… For women before the age of 60 or within 10 years of menopause, MHT has a favorable benefit-risk profile.”

These are consistent with each other and represent the current medical consensus, in contrast to the post-2002 fear period.

---

Contraindications: Who Should Not Take HRT

Absolute contraindications for hormone therapy:

• Personal history of hormone-sensitive breast cancer (ER/PR positive) — some types; specialist consultation required for all breast cancer history
• Active blood clot or recent stroke — within 6 months
• Unexplained vaginal bleeding — requires evaluation before HRT
• Active liver disease
• Known or suspected pregnancy

Women with BRCA1/2 mutations, a first-degree relative with early-onset breast cancer, or personal history of blood clots require specialist consultation rather than telehealth initiation.

The Winona intake process screens for all listed contraindications. A board-certified physician reviews every health intake form before prescribing. Women with contraindications will not receive a prescription.

---

The picture on HRT safety is substantially more nuanced and more favorable than the 2002 headlines suggested. For the majority of symptomatic women in the timing window, the current evidence supports initiation. The right starting point is a physician assessment — which is what telehealth platforms like Winona provide.

[For a comparison of bioidentical HRT versus non-hormonal alternatives, see Menopause Treatment Options Compared 2026.] [For early perimenopause symptom recognition and when to start HRT, see Perimenopause Starts at 35 — Here’s What to Watch For.] [To see the full Winona protocol and what to expect in the first 90 days, see 90 Days on Winona Bioidentical HRT.]

---

This article is informational only and does not constitute medical advice. Consult your physician before starting hormone therapy. Individual responses to HRT vary. This article contains affiliate links — Verto earns a commission when you start a Winona program through our links, at no additional cost to you.